EPO grants GH Research patent with claims directed to 5-MeO-DMT for MDD/TRD

GH Research announced that it recently received a communication from the European Patent Office or EPO, that it has been granted a patent with claims directed to mebufotenin or 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder MDD and treatment-resistant forms of MDD, such as treatment-resistant depression or TRD. The newly granted patent, EP3927337, which will have an effective date of February 14 and an expiry date of no earlier than 2040, is expected to cover all mebufotenin 5-MeO-DM and mebufotenin salt products for use in the treatment of MDD and TRD, including but not limited to products administered through pulmonary inhalation, intravenous and intranasal routes. It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments. Similar patent applications are pending on behalf of the company in the US and in over thirty other jurisdictions, aiming to provide broad coverage in all key geographies for the therapeutic use of mebufotenin in MDD and TRD…Theis Terwey, CEO and Co-founder of GH Research said: “We are committed to providing highly effective new therapies to patients in mental health care who are underserved by existing treatments. Having a strong IP portfolio helps us with this mission, and it is satisfying to have the EPO endorse the strength of our IP…”